BIOFRONTERA AG (B8FK.DE) Fundamental Analysis & Valuation

FRA:B8FK • DE000A4BGGM7

Current stock price

2.59 EUR
-0.02 (-0.77%)
Last:

This B8FK.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. B8FK.DE Profitability Analysis

1.1 Basic Checks

  • B8FK had negative earnings in the past year.
  • In the past year B8FK had a positive cash flow from operations.
  • In the past 5 years B8FK reported 4 times negative net income.
  • In the past 5 years B8FK reported 4 times negative operating cash flow.
B8FK.DE Yearly Net Income VS EBIT VS OCF VS FCFB8FK.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

  • B8FK has a Return On Assets of -12.27%. This is in the lower half of the industry: B8FK underperforms 73.08% of its industry peers.
  • With a Return On Equity value of -18.00%, B8FK is not doing good in the industry: 71.15% of the companies in the same industry are doing better.
  • The Return On Invested Capital of B8FK (0.59%) is worse than 65.38% of its industry peers.
Industry RankSector Rank
ROA -12.27%
ROE -18%
ROIC 0.59%
ROA(3y)-50.22%
ROA(5y)N/A
ROE(3y)-80.64%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
B8FK.DE Yearly ROA, ROE, ROICB8FK.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 50 -50 -100 -150 -200

1.3 Margins

  • With a Operating Margin value of 0.56%, B8FK is not doing good in the industry: 65.38% of the companies in the same industry are doing better.
  • B8FK's Gross Margin of 78.43% is amongst the best of the industry. B8FK outperforms 80.77% of its industry peers.
  • In the last couple of years the Gross Margin of B8FK has declined.
Industry RankSector Rank
OM 0.56%
PM (TTM) N/A
GM 78.43%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.43%
GM growth 5YN/A
B8FK.DE Yearly Profit, Operating, Gross MarginsB8FK.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 100 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. B8FK.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so B8FK is destroying value.
  • Compared to 1 year ago, B8FK has more shares outstanding
  • Compared to 1 year ago, B8FK has an improved debt to assets ratio.
B8FK.DE Yearly Shares OutstandingB8FK.DE Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2M 4M 6M
B8FK.DE Yearly Total Debt VS Total AssetsB8FK.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of -5.12, we must say that B8FK is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -5.12, B8FK is doing worse than 78.85% of the companies in the same industry.
  • The Debt to FCF ratio of B8FK is 0.33, which is an excellent value as it means it would take B8FK, only 0.33 years of fcf income to pay off all of its debts.
  • B8FK has a better Debt to FCF ratio (0.33) than 98.08% of its industry peers.
  • A Debt/Equity ratio of 0.01 indicates that B8FK is not too dependend on debt financing.
  • B8FK has a Debt to Equity ratio of 0.01. This is amongst the best in the industry. B8FK outperforms 92.31% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.33
Altman-Z -5.12
ROIC/WACC0.08
WACC7.32%
B8FK.DE Yearly LT Debt VS Equity VS FCFB8FK.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

  • B8FK has a Current Ratio of 2.47. This indicates that B8FK is financially healthy and has no problem in meeting its short term obligations.
  • B8FK's Current ratio of 2.47 is fine compared to the rest of the industry. B8FK outperforms 76.92% of its industry peers.
  • A Quick Ratio of 1.81 indicates that B8FK should not have too much problems paying its short term obligations.
  • B8FK has a better Quick ratio (1.81) than 82.69% of its industry peers.
Industry RankSector Rank
Current Ratio 2.47
Quick Ratio 1.81
B8FK.DE Yearly Current Assets VS Current LiabilitesB8FK.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. B8FK.DE Growth Analysis

3.1 Past

  • The earnings per share for B8FK have decreased by -8.46% in the last year.
  • The Revenue has been growing slightly by 7.14% in the past year.
  • Measured over the past years, B8FK shows a decrease in Revenue. The Revenue has been decreasing by -9.04% on average per year.
EPS 1Y (TTM)-8.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-82.5%
Revenue 1Y (TTM)7.14%
Revenue growth 3Y-9.04%
Revenue growth 5YN/A
Sales Q2Q%-14.4%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y124.55%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year22.18%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
B8FK.DE Yearly Revenue VS EstimatesB8FK.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
B8FK.DE Yearly EPS VS EstimatesB8FK.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

4

4. B8FK.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for B8FK. In the last year negative earnings were reported.
  • The Price/Forward Earnings ratio is 23.64, which indicates a rather expensive current valuation of B8FK.
  • B8FK's Price/Forward Earnings is on the same level as the industry average.
  • When comparing the Price/Forward Earnings ratio of B8FK to the average of the S&P500 Index (23.84), we can say B8FK is valued inline with the index average.
Industry RankSector Rank
PE N/A
Fwd PE 23.64
B8FK.DE Price Earnings VS Forward Price EarningsB8FK.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

  • B8FK's Enterprise Value to EBITDA ratio is in line with the industry average.
  • B8FK's Price/Free Cash Flow ratio is rather cheap when compared to the industry. B8FK is cheaper than 90.38% of the companies in the same industry.
Industry RankSector Rank
P/FCF 9.66
EV/EBITDA 14.94
B8FK.DE Per share dataB8FK.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

  • B8FK's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. B8FK.DE Dividend Analysis

5.1 Amount

  • No dividends for B8FK!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

B8FK.DE Fundamentals: All Metrics, Ratios and Statistics

BIOFRONTERA AG

FRA:B8FK (3/13/2026, 7:00:00 PM)

2.59

-0.02 (-0.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-30
Earnings (Next)03-31
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners12.23%
Ins Owner ChangeN/A
Market Cap15.75M
Revenue(TTM)23.22M
Net Income(TTM)-2.70M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 23.64
P/S 0.68
P/FCF 9.66
P/OCF 8.47
P/B 1.02
P/tB 1.02
EV/EBITDA 14.94
EPS(TTM)-0.45
EYN/A
EPS(NY)0.11
Fwd EY4.23%
FCF(TTM)0.27
FCFY10.35%
OCF(TTM)0.31
OCFY11.81%
SpS3.82
BVpS2.53
TBVpS2.53
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -12.27%
ROE -18%
ROCE 0.84%
ROIC 0.59%
ROICexc 0.59%
ROICexgc 0.59%
OM 0.56%
PM (TTM) N/A
GM 78.43%
FCFM 7.02%
ROA(3y)-50.22%
ROA(5y)N/A
ROE(3y)-80.64%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.43%
GM growth 5YN/A
F-Score6
Asset Turnover1.06
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.33
Debt/EBITDA 0.11
Cap/Depr 23.96%
Cap/Sales 0.99%
Interest Coverage 250
Cash Conversion 170.64%
Profit Quality N/A
Current Ratio 2.47
Quick Ratio 1.81
Altman-Z -5.12
F-Score6
WACC7.32%
ROIC/WACC0.08
Cap/Depr(3y)90.56%
Cap/Depr(5y)N/A
Cap/Sales(3y)2.53%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-82.5%
EPS Next Y124.55%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)7.14%
Revenue growth 3Y-9.04%
Revenue growth 5YN/A
Sales Q2Q%-14.4%
Revenue Next Year22.18%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y105.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year131.82%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y2.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.98%
OCF growth 3YN/A
OCF growth 5YN/A

BIOFRONTERA AG / B8FK.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of BIOFRONTERA AG (B8FK.DE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to B8FK.DE.


Can you provide the valuation status for BIOFRONTERA AG?

ChartMill assigns a valuation rating of 4 / 10 to BIOFRONTERA AG (B8FK.DE). This can be considered as Fairly Valued.


What is the profitability of B8FK stock?

BIOFRONTERA AG (B8FK.DE) has a profitability rating of 1 / 10.


How financially healthy is BIOFRONTERA AG?

The financial health rating of BIOFRONTERA AG (B8FK.DE) is 6 / 10.